Supply Shock August: SpaceX Lockups, a Biotech Filing Wave, and a Liquidity Drain Collide

The IPO market just completed the strongest first half on record, and the second half opens with a test of how much supply the market can actually absorb. Three forces are converging in the first two weeks of August: roughly $123 billion in SpaceX insider shares unlock from their post-IPO lockup, a wave of biotech S-1 filings is queuing up to price, and Jersey Mike’s is testing whether investor appetite extends beyond gene-editing into franchise restaurants. Meanwhile, the plumbing underneath all of this is showing strain — order-book depth has contracted even as headline trading volume surges, and the Treasury’s borrowing plans could drain an estimated $350 billion in liquidity by mid-September. The question is not whether new supply is coming. It is whether the market’s absorptive capacity is expanding fast enough to meet it.

The SpaceX Lockup Cliff

SpaceX (SPCX) closed the largest IPO in history on June 12, 2026, raising $75 billion at a set price of $135 per share.^[1] Roughly 555.6 million shares were sold to public investors — about 4% of the company’s total equity.^[2] That constrained float propelled shares to a peak of $225.64 before gravity set in. By mid-July, the stock had slid to approximately $131, dipping below its IPO price for the first time.^[2]

The bigger supply event is still ahead. Multiple reports cite approximately $123 billion in locked-up shares scheduled to begin unlocking in early August.^[2] Short interest has climbed to nearly one-third of the public float as of mid-July, a rapid buildup that signals traders are already positioning for the supply overhang.^[2]

There is genuine uncertainty about how much of that $123 billion actually hits the market. Lockup expiries release the option to sell, not the obligation. Some insiders will hold. Some will use 10b5-1 plans to sell gradually. But the math is stark: if even 10% of the unlocked shares are sold, that is roughly $12 billion in new supply hitting a stock with a 4% free float. The ratio of potential new supply to existing float is what makes this event unusual. Most large IPOs have lockup expiries that release shares equal to 5-15x the offering size. For SpaceX, the unlocked shares could be 20x or more of the initial float.

I would put the probability of meaningful post-lockup selling at roughly 65/35 — leaning toward selling pressure but acknowledging that Musk’s insider cohort has historically been sticky. The key variable is whether early investors who have been holding private SpaceX equity for a decade decide the public market is finally their exit. That is a liquidity preference decision, not a valuation decision, and it tends to be sticky once made.

The Biotech Filing Wave

While SpaceX dominates the supply narrative, the IPO filing pipeline is quietly building its own momentum. At least ten S-1 and S-1/A filings landed at the SEC in the week of July 22-24 alone, spanning biotech, eyewear, batteries, and identity verification.^[3] The biotech sector is the standout: twelve new S-1 filings in a recent cluster signal what one tracker called a “micro-cap biotech wave,” with companies including Attovia Therapeutics (filed July 14), Apnimed (July 10), Valion Bio (July 17), and Lyntris Inc. (July 23) all registering.^[4][3]

The first deal of this second-half biotech run has already priced. Scribe Therapeutics (SCTX), a CRISPR gene-editing company co-founded by Jennifer Doudna, upsized its offering to 8.58 million shares at $15 — the high end of its $13-$15 range — raising $128.7 million on July 23.^[5] The stock closed its first day at $21.65, a 44% gain, and traded as high as $25 intraday.^[5]

That first-day pop is a signal worth reading carefully. Biotech IPOs in 2025 were largely priced at the low end or withdrawn entirely. A deal that priced at the high end and then traded 44% above its offer price suggests the bid for clinical-stage biotech has materially improved. The underlying driver appears to be venture funding: first-half 2026 biotech venture investment reached $9.1 billion across 68+ companies, the strongest H1 biotech funding tally since 2022.^[3] That capital has to go somewhere, and the public markets are the natural exit.

The filing pipeline suggests this is not a one-off. The pipeline of S-1s typically translates to priced deals six to ten weeks later, which means the biotech supply wave likely runs through September and October.

Jersey Mike’s Tests Consumer Appetite

The week of July 28 brings a different kind of supply test. Jersey Mike’s Subs (JMKE), a Blackstone-backed franchise sandwich chain with over 3,000 U.S. locations, launched its roadshow on July 20 with 43.5 million Class A shares at a $21-$25 range.^[1] At the midpoint, the deal raises approximately $1.0 billion; at the high end, up to $1.09 billion.^[1] The implied market cap at the midpoint sits near $7.3 billion, with the high end pushing toward $7.9 billion.^[1]

Notably, roughly 68% of the offering is secondary — shares sold by existing stockholders, not the company.^[1] That means the deal is primarily a liquidity event for insiders, including Blackstone, rather than growth capital. Net proceeds to the company are approximately $301 million, with the bulk of the money flowing to selling stockholders.^[1] The targeted trading debut is July 30 on the NYSE.^[1]

This is the first sizable consumer/restaurant IPO of the second half, and it arrives at a valuation that Fortune notes could be roughly eight times Sweetgreen’s market cap — a company in the same fast-casual space.^[1] The question is whether public-market investors who have been buying biotech will also absorb a franchise restaurant at a premium multiple. The 68% secondary component adds a layer: it is not just a new listing, it is insiders cashing out at the top of the range. That is a rational thing for them to do, but it is also a signal about where the sellers think we are in the cycle.

The Liquidity Backdrop

All of this supply is arriving into a market where the plumbing is flashing warning signs. Institutional trading volumes have surged to approximately $4.2 trillion weekly, yet order-book depths have contracted 23% since Q1 2026, according to data cited from JPMorgan and Goldman Sachs.^[6] That means more volume is trading through thinner books — a classic sign of liquidity fragmentation, where headline volume masks deteriorating execution quality and wider effective spreads.

Separately, the Treasury’s net bill issuance plans could drain an estimated $350 billion in liquidity by mid-September, with the Fed’s reverse repo facility nearly depleted.^[6] This matters because new IPO supply competes for the same marginal dollar of liquidity. When reserves are being drained, the bid behind new issuance weakens.

A piece published July 26 argues that liquidity headwinds are building as the dispersion trade — a popular strategy that benefited from single-stock volatility — begins to fade.^[6] If that trade unwinds, it removes a source of structural demand for the very single-stock optionality that IPO supply depends on.

First Half by the Numbers

The gap between record proceeds and a declining deal count tells the story: 2026 is a market of large deals, not a broad market. The SpaceX deal alone accounted for more than half of Q2 proceeds.^[7] Strip it out and the IPO market is healthy but not extraordinary — steady, with a bias toward larger, higher-quality issuers.

What to Watch Next

1. SpaceX lockup expiry (early August): Watch for 10b5-1 plan filings and Form 4 sales in the days after the lockup lifts. The pace of insider selling — not the fact of it — will determine whether SPCX stabilizes or re-rates lower. Short interest near one-third of float means any positive surprise (slow selling, continued holding) could trigger a short squeeze.

2. Jersey Mike’s debut (July 30): The first-day performance will signal whether investor appetite extends to consumer/franchise IPOs or remains concentrated in biotech and AI. A break below the $21 low end on the first day would be a negative read for the broader IPO market’s breadth.

3. Biotech S-1 conversion rate: Of the 10+ filings from the week of July 22-24, how many price within 60 days? A high conversion rate means the window is genuinely open. A wave of withdrawals or postponements would signal that the Scribe pop was an anomaly, not a trend.

4. Treasury liquidity drain (through mid-September): Watch the Fed’s reverse repo facility balance and bank reserve levels. If reserves contract faster than expected, expect wider IPO discounts and smaller deal sizes as underwriters adjust to thinner liquidity.

5. Order-book depth metrics: If the 23% contraction in depth since Q1 continues into August, the cost of absorbing new supply rises for every buyer. That shows up first in the bid-ask spreads of newly listed stocks.

The trajectory is clear: record supply is meeting a liquidity environment that is tightening, not loosening. The base case is that the market absorbs the biotech wave and Jersey Mike’s without major disruption — call it 60/40 in favor of orderly absorption — but the SpaceX lockup is the tail risk that could re-price the entire IPO cohort if insider selling is heavier than the thin float can handle. By mid-September, when the Treasury drain peaks and the first wave of biotech deals has priced, we will know whether 2026’s record first half was a sustainable reopening of the IPO window or a spike followed by a supply-driven correction.

---

FN2 Research provides financial research and education, not personalized investment advice. This article does not constitute a recommendation to buy, sell, or hold any security.

Sources

1. Jersey Mike's Announces Launch of Initial Public Offeringprnewswire.com
2. Here's What Retail Investors Need to Know About SpaceX's Lockup Cliff | The Motley Foolfool.com
3. 12 New S-1 Filings Show a Micro-Cap Biotech Wave | Value Add Pulsevalueaddvc.com
4. S-1sec.gov
5. Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPOfinance.yahoo.com
6. Monetary Policy Report, July 2026federalreserve.gov
7. 2Q26 US Reviewrenaissancecapital.com